Search
memantine clinical trials
3 studies: 24 & 28 weeks,
- 2 studies used memantine 20 mg/day, one in combination with donepezil [1,2]
- 1 study used 5-20 mg of memantine in combination with donepezil [3]
- all 3 studies showed improvement in cognitive function & activities of daily living relative to placebo or donepezil alone
- improvement modest
a) 3.4 points on a 100 point scale of cognitive function
b) 1.5 points on a 54 point activities of daily living scale
Summary & Clinical practice guideline [4,5]
- statistically significant but clinically marginal improvement in measures of cognition & global assessment of dementia
- most studies were of short duration (6 months); this limits their ability to detect delay in onset or progression of dementia
General
clinical trial
References
- Journal Watch 23(10):80, 2003
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S,
Mobius HJ; Memantine Study Group.
Memantine in moderate-to-severe Alzheimer's disease.
N Engl J Med. 2003 Apr 3;348(14):1333-41.
PMID: 12672860
- Prescriber's Letter 10(11) 2003; detail document 191102
http://www.namenda.com
- Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S,
Gergel I; Memantine Study Group.
Memantine treatment in patients with moderate to severe
Alzheimer disease already receiving donepezil: a randomized
controlled trial.
JAMA. 2004 Jan 21;291(3):317-24.
PMID: 14734594
- Raina P et al
Effectiveness of cholinesterase inhibitors and memantine for
treating dementia: evidence review for a clinical practice
guideline.
Ann Intern Med. 2008 Mar 4;148(5):379-97
PMID: 18316756
- Kavirajan H, Schneider LS
Efficacy and adverse effects of cholinesterase inhibitors
and memantine in vascular dementia: a meta-analysis of
randomised controlled trials.
Lancet Neurol. 2007 Sep;6(9):782-92
PMID: 17689146